Clinical

The AJMC^® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care^® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.

Latest News

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

By Laura Joszt, MA
Eileen Peng, PharmD

May 21st 2025

The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.

AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

By Laura Joszt, MA
Harsh Parmar, MD

May 17th 2025

Among patients in the real-world setting, acalabrutinib was associated with reduced risks of AF or flutter and a reduced risk of hypertension. | Image credit: inthasone - stock.adobe.com

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

By AJMC Contributor

May 17th 2025

Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com

Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

By AJMC Contributor

May 16th 2025

Hospital exterior | Image Credit: Spiroview Inc. - stock.adobe.com

Access to Minimally Invasive Surgery for Advanced Ovarian Cancer Varies Widely by Facility

By Brooke McCormick

May 16th 2025

More News

Entering a 4-Drug Regimen for Multiple Myeloma Treatment

June 28th 2019

Watch

MAIA Trial: Transplant-Ineligible Patients With MM

June 28th 2019

Watch

Using MRD Negativity to Stop Maintenance Therapy in MM

June 28th 2019

Watch

Long-term Data on Improving OS for Patients With MM

June 28th 2019

Watch

Payer Perspective: Transplant and Toxicities in MM Therapy

June 28th 2019

Watch

FORTE Trial: Transplant in Patients with Multiple Myeloma

June 28th 2019

Watch

Impact of Maintenance Therapy in Multiple Myeloma

June 28th 2019

Watch

Strategy for Up-front Therapy of Multiple Myeloma

June 28th 2019

Watch

Backbone Therapy in Newly Diagnosed Multiple Myeloma

June 28th 2019

Watch

How Real-World Data Can Address Problems in MM

June 28th 2019

Watch

$Dosing Strategies in Relapsed-Refractory MM$

Dosing Strategies in Relapsed-Refractory MM

June 28th 2019

Watch

$Initiating Treatment in Relapsed-Refractory MM$

Initiating Treatment in Relapsed-Refractory MM

June 28th 2019

Watch

What Is the Cost of Recurrence in Multiple Myeloma?

June 28th 2019

Watch

Daratumumab in the Treatment Landscape for MM

June 28th 2019

Watch

Clinical Significance of MRD Testing in MM

June 28th 2019

Watch

Practical Implications of the MAIA Study for MM

June 28th 2019

Watch

Considerations for Transplant-Ineligible Patients

June 28th 2019

Watch

NCCN Guidelines for Newly Diagnosed MM

June 28th 2019

Watch

Achieving the Best Outcomes for Patients With MM

June 28th 2019

Watch

Cost Considerations of Multidrug Regimens in MM

June 28th 2019

Watch

Factoring Age Into Frontline Therapy for MM

June 28th 2019

Watch

Individualizing Therapy for Multiple Myeloma Patients

June 28th 2019

Watch

June Halper Outlines the Biggest Management Challenges in Multiple Sclerosis

June 22nd 2019

The biggest clinical challenges that we have in treating multiple sclerosis are 2-fold, explained June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers.

Watch

Evaluating Use of Bone-Modifying Agents to Treat Skeletal-Related Events in Cancer

Laura Joszt, MA

June 15th 2019

Skeletal-related events are frequent complications in patients with cancers. Two abstracts analyzed the use of bone-modifying agents in patients with newly diagnosed multiple myeloma and breast cancer.

Identifying Biomarkers to Predict Disease Severity, Progression, and Cognitive Impairment in MS

Laura Joszt, MA

June 6th 2019

Two abstracts presented at the 33rd Annual Meeting of the Consortium of Multiple Sclerosis Centers analyzed biomarkers to predict progression, disease severity, and cognitive impairment in multiple sclerosis (MS).